Literature DB >> 9495246

MAGE-11 protein is highly conserved in higher organisms and located predominantly in the nucleus.

M Jurk1, E Kremmer, U Schwarz, R Förster, E L Winnacker.   

Abstract

The MAGE-11 gene belongs to a family whose products were identified first in tumor tissue. The MAGE-11 gene product has not been characterized in detail. We have isolated MAGE-11 cDNA from HeLa cells and confirmed the presence of MAGE-11 protein and of at least 2 other MAGE proteins (MAGE-1 and MAGE-3) in this cell line. Monoclonal antibodies (MAbs), obtained by using a GST-MAGE-11 fusion protein, detect MAGE-11 protein in HeLa cells as a 48 kDa protein. In contrast to other known proteins of the MAGE family, MAGE-11 is found mainly in the nucleus. Immunoprecipitation out of whole-cell extracts from different species reveals that MAGE-11 protein is highly conserved among mammalian cells, suggesting a conserved and important function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9495246     DOI: 10.1002/(sici)1097-0215(19980302)75:5<762::aid-ijc16>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11.

Authors:  Smitha R James; Carlos D Cedeno; Ashok Sharma; Wa Zhang; James L Mohler; Kunle Odunsi; Elizabeth M Wilson; Adam R Karpf
Journal:  Epigenetics       Date:  2013-07-09       Impact factor: 4.528

2.  Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction.

Authors:  Suxia Bai; Bin He; Elizabeth M Wilson
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

3.  Androgen receptor molecular biology and potential targets in prostate cancer.

Authors:  Elizabeth M Wilson
Journal:  Ther Adv Urol       Date:  2010-06

4.  Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.

Authors:  Olga Aprelikova; Silvia Pandolfi; Sean Tackett; Mark Ferreira; Konstantin Salnikow; Yvona Ward; John I Risinger; J Carl Barrett; John Niederhuber
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

5.  MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.

Authors:  Elena Grau; Silvestre Oltra; Francisco Martínez; Carmen Orellana; Adela Cañete; Jose María Fernández; Miguel Hernández-Martí; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-27       Impact factor: 4.553

6.  MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription.

Authors:  Sandra Laduron; Rachel Deplus; Sifang Zhou; Olga Kholmanskikh; Danièle Godelaine; Charles De Smet; S Diane Hayward; François Fuks; Thierry Boon; Etienne De Plaen
Journal:  Nucleic Acids Res       Date:  2004-08-17       Impact factor: 16.971

Review 7.  Emerging roles of the MAGE protein family in stress response pathways.

Authors:  Rebecca R Florke Gee; Helen Chen; Anna K Lee; Christina A Daly; Benjamin A Wilander; Klementina Fon Tacer; Patrick Ryan Potts
Journal:  J Biol Chem       Date:  2020-09-13       Impact factor: 5.157

8.  Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.

Authors:  P Chaux; V Vantomme; V Stroobant; K Thielemans; J Corthals; R Luiten; A M Eggermont; T Boon; P van der Bruggen
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

9.  NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens.

Authors:  E Schultz-Thater; C Noppen; F Gudat; U Dürmüller; P Zajac; T Kocher; M Heberer; G C Spagnoli
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

10.  Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma.

Authors:  K Kariyama; T Higashi; Y Kobayashi; K Nouso; H Nakatsukasa; T Yamano; M Ishizaki; T Kaneyoshi; N Toshikuni; T Ohnishi; K Fujiwara; E Nakayama; L Terracciano; G C Spagnoli; T Tsuji
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.